Fusen Pharmaceutical Valuation
Is 1652 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 1652 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 1652's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 1652's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1652?
Key metric: As 1652 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 1652's PS Ratio? | |
|---|---|
| PS Ratio | 1.5x |
| Sales | CN¥425.49m |
| Market Cap | CN¥619.06m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.3x |
| Enterprise Value/EBITDA | -44.4x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 1652's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.4x | ||
503 Lansen Pharmaceutical Holdings | 1.5x | n/a | HK$750.6m |
8049 Jilin Province Huinan Changlong Bio-pharmacy | 0.9x | n/a | HK$790.0m |
3737 Zhongzhi Pharmaceutical Holdings | 0.4x | n/a | HK$777.2m |
239 Pak Fah Yeow International | 2.9x | n/a | HK$760.4m |
1652 Fusen Pharmaceutical | 1.5x | n/a | HK$665.4m |
Price-To-Sales vs Peers: 1652 is expensive based on its Price-To-Sales Ratio (1.5x) compared to the peer average (1.4x).
Price to Sales Ratio vs Industry
How does 1652's PS Ratio compare vs other companies in the HK Pharmaceuticals Industry?
| 4 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
3320 China Resources Pharmaceutical Group | 0.1x | 8.0% | US$4.30b |
897 Wai Yuen Tong Medicine Holdings | 0.3x | n/a | US$30.07m |
8329 Shenzhen Neptunus Interlong Bio-technique | 0.2x | n/a | US$29.97m |
1312 Kontafarma China Holdings | 0.2x | n/a | US$22.26m |
| 4 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: 1652 is expensive based on its Price-To-Sales Ratio (1.5x) compared to the Hong Kong Pharmaceuticals industry average (1.5x).
Price to Sales Ratio vs Fair Ratio
What is 1652's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.5x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 1652's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
3SBio
HK$13.4b
An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.
1530
HK$5.69
7D
-2.4%
1Y
-23.1%
China Shineway Pharmaceutical Group
HK$6.2b
An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.
2877
HK$8.27
7D
-0.7%
1Y
n/a
United Laboratories International Holdings
HK$18.5b
An investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products.
3933
HK$10.16
7D
0.4%
1Y
28.4%